Health Care/Hospital
CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the Orphan-drug Designation by the Food and Drug Administration of the United States
CHENGDU, China, April 12, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that its new drug candidate CMG901 (the "Claudin 18.2 antibody drug conjugates") for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma has been granted the Orphan-drug Designation by t...
2022-04-12 15:45
711
/DISREGARD RELEASE: HanAll Biopharma and Daewoong Pharmaceutical/
We are advised by HanAll Biopharma and Daewoong Pharmaceutical that journalists and other readers should disregard the news release, "Daewoong Pharmaceutical and HanAll Biopharma Invest in Turn Biotechnologies to Expand Growth Initiative", issued11-Apr-2022 over PR Newswire. ...
2022-04-12 15:34
1621
PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022
DAEJEON, South Korea, April 11, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), aclinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company presented an updated preclinical data PMC-309, the Company's anti-VISTA ...
2022-04-11 20:00
751
InventisBio Reported Promising Phase I Study Results of a Novel KRAS G12C Inhibitor D-1553 in Cancer Patients
SHANGHAI, April 11, 2022 /PRNewswire/ -- InventisBio Co., Ltd., a clinical-stage biotech company based inShanghai, China has published the clinical data of their oral KRAS G12C inhibitor D-1553, for the first time in cancer patients. These data are presented in two e-posters at the annual meetin...
2022-04-11 17:37
620
Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL
Allogeneic, off-the-shelf CAR-T therapy with CD19/CD7 dual-directed CAR shows promising early results in patients with r/r B-ALL PALO ALTO, Calif. and SUZHOU, China, April 8, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage bio...
2022-04-09 04:00
3392
KAZIA THERAPEUTICS ANNOUNCES PRECLINICAL DATA PRESENTED AT AACR CONFERENCE BY JOHNS HOPKINS UNIVERSITY SHOWING ACTIVITY OF PAXALISIB IN PAEDIATRIC BRAIN TUMOURS
SYDNEY, April 8, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce new preclinical data demonstrating the activity of paxalisib in two forms of childhood brain cancer with very high unmet medical need. ...
2022-04-08 20:30
3304
TWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I STUDY OF EVT801 IN ADVANCED CANCER
SYDNEY, April 8, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company, is pleased to announce two presentations detailing the ongoing phase I study of the company's investigational novel drug, EVT801, a selective VEGFR3 ...
2022-04-08 20:00
3098
OliX Pharmaceuticals Identifies Inhibition of Target Gene Expression in Nonhuman Primate Models for NASH Candidate
* Identified knockdown of target genes for the NASH treatment candidate * Reduction of ALT and AST liver marker levels observed in monkey models * Company to present results at the 2022 Academic Symposium of the Korean Endocrine Society SUWON, South Korea, April 8, 2022 /PRNewswire/ -- OliX ...
2022-04-08 20:00
2952
AGC to Expand Synthetic Pharmaceutical Production Base in Spain
TOKYO, April 8, 2022 /PRNewswire/ -- AGC Inc. (hereinafter "AGC"), a Tokyo -based world-leading manufacturer of glass, chemicals, high-tech materials, has decided to expand the facilities of AGC Pharma Chemicals Europe S.L.U. (hereinafter "APCE"), an AGC subsidiary in Spain engaged in the syntheti...
2022-04-08 14:00
1820
WuXi AppTec Recognized as Top-Rated ESG Company by Sustainalytics
SHANGHAI, April 7, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, received an ESG Risk Rating, recognizing it as a "Top Rated" performing company from Sustainalytics as of March, 2022. W...
2022-04-08 08:00
1922
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer
SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr.Raffaele Baffa ("Dr. Baffa") has been appointed as...
2022-04-07 23:42
2460
SeekIn Receives CE Mark Approval for LeukoPrint® Molecular Karyotyping Test
First-of-its-Kind Molecular Karyotyping Test SHENZHEN, China, April 7, 2022 /PRNewswire/ -- SeekIn Inc, the leader in blood-based cancer early detection and monitoring technology, today announced the CE (Conformité Européenne) Mark for LeukoPrint® Molecular Karyotyping Kit and is now ready to la...
2022-04-07 22:22
1759
REDCLOUD BIO TO PRESENT PRECLINICAL DATA OF NEXT-GENERATION EGFR TKI H002 AT ANNUAL MEETING OF AMERICAN ASSOCIATION OF CANCER RESEARCH
SHANGHAI, April 7, 2022 /PRNewswire/ -- RedCloud Bio (the "Company"), an innovative biotech company integrating structural pharmacology and computational approaches to advance small molecule drug development, announced the upcoming presentation of preclinical data of H002, a next-generation epid...
2022-04-07 19:47
1414
Psychobiotic PS128 Registration, Health Claims Approved in Thailand, Canada
TAIPEI, April 6, 2022 /PRNewswire/ -- Bened Biomedical announced recent approval of the company's probioticL. plantarum PS128 in Thailand and Canada. Authorities in each country also endorsed health claims that may be made about the strain. Local distributors will launch PS128 products this year....
2022-04-07 11:20
1358
Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting
* The data provides further validation of the intended Phase 2 study design MELBOURNE, Australia and SAN FRANCISCO, April 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treat...
2022-04-07 09:34
1873
Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, April 6, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", "the Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, today announced a glob...
2022-04-07 09:09
1691
ENSEM Therapeutics, a CBC Group-Incubated Biopharma Company, Raises $67 Million in Series A Financing to Develop Small Molecule Medicines for Difficult-to-Drug Targets
BOSTON, April 6, 2022 /PRNewswire/ -- ENSEM Therapeutics Inc. (ENSEM), a Boston -based biotechnology company focusing on high value and difficult-to-drug oncology targets, announced today the closing of a series A2 financing. Incubated by CBC group since 2021, the financing is led by GGV Capital, ...
2022-04-07 04:00
1900
HitGen and UPPTHERA Extend PROTAC Research Collaboration after Hit Finding Success on Undruggable Targets
CHENGDU, China, April 6, 2022 /PRNewswire/ -- HitGen Inc. ("HitGen"), a Shanghai Stock Exchange STAR-listed company (ticker code 688222.SH), today announced that the company has successfully completed the multiple-target drug discovery research projects with UPPTHERA, a Korean pharmaceutical comp...
2022-04-06 22:30
2197
New Studies at AACR 2022 Highlight Lunit SCOPE's Immune Phenotyping Capabilities
* Lunit to present two abstracts about its AI-biomarker for immunotherapy, Lunit SCOPE IO * Lunit will deliver an oral presentation on its breakthrough study supporting the effectiveness of Lunit SCOPE IO as a prognostic biomarker for endometrial cancer SEOUL, South Korea, April 6, 2022 /PRNe...
2022-04-06 21:44
1888
China Jo-Jo Drugstores, Inc. Announces 1-for-12 Reverse Stock Split
HANGZHOU, China, April 6, 2022 /PRNewswire/ – China Jo-Jo Drugstores, Inc. (" Jo-Jo Drugstores" or the "Company") (Nasdaq: CJJD), a Cayman Islands company, reported that it expects to implement a 1-for-12 reverse stock split on its ordinary shares effectiveThursday, April 7, 2022, with trading to ...
2022-04-06 21:15
3395
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 301 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00TAILG's First Flagship Store in Indonesia Grandly Opens
[Picked up by 283 media titles]
2024-11-22 21:59
MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
10677
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
6792
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
6771
